Osmind

We are excited to announce a landmark collaboration with the American Psychiatric Association (APA) to advance quality psychiatric care and accelerate research. "At Osmind, we emphasize the importance of clinicians participating in evidence-generating medicine to help shape the future of mental health care, especially as the psychiatric field begins to embrace new treatments and precision psychiatry,” says Carlene MacMillan, MD, Chief Medical Officer of Osmind. “Clinicians in private practice juggle many competing demands so it is crucial we make participation both easy and worthwhile to them." To make participation in evidence-generating medicine easier for busy private practitioners, we’re integrating APA's diagnostic and outcomes measures directly into the Osmind EHR. We're starting with the DSM-5-TR Self-Rated Level 1 Cross-Cutting Symptom Measure, which joins our library of 40+ measures, enabling clinicians to contribute to research at the point of care. We’ll also explore an integration between the Osmind EHR and PsychPRO so that clinicians using the Osmind EHR can participate effortlessly in the PsychPRO registry. "PsychPRO is the tool healthcare organizations need to guide their efforts to deliver quality mental health care and improve patient outcomes," says Nitin Gogtay, M.D., APA Chief of Research and Deputy Medical Director. "Our collaboration with Osmind will allow us to strengthen PsychPRO today, and long-term offers promise to broaden the scope of our impact on psychiatry and on the patients we serve.” We are delighted to work with the APA, and proud to enable independent practices to contribute to the evolution of the field and elevate their own evidence-based practices. https://lnkd.in/g4RU7Ftt

"This is what I've wanted for a long time, even if you're practicing in a giant medical center, it's way too easy day after day to feel like you're all alone. Come on over to the Psychiatry Collective, post and interact, let's really get into the future of mental health together!" -Will Sauve, MD "Are you a mental health clinician or practice owner? Have you joined the Psychiatry Collective? Facebook blocks words like "ketamine" and listservs are so early 2K. The Psychiatry Collective is an elegant platform and a vibrant professional community which has become my go-to to connect, to learn and move our field forward." - Carlene MacMillan, MD "The Osmind Community is a terrific resource for forward thinking psychiatrists. We have experts piloting a host of novel technologies and dialing in on breaking news from start up companies in the space. From clinical trials opportunities and insurance reimbursement strategies to note templates and supply chain information we have so much to offer. And it is a warm, friendly space ??. Please consider joining us!" - Alison McInnes, MD, MS

Are you a mental health clinician or practice owner? Have you joined the Psychiatry Collective? Facebook blocks words like ketamine and listservs are so early 2K. The Psychiatry Collective is an elegant platform and a vibrant professional community which has become my go-to to connect, to learn and move our field forward. Join us! https://lnkd.in/eUt8Jfrm

BREAKING: Osmind Psychiatry Collective Opens to All Mental Health Clinicians Osmind is expanding our community beyond EHR users. The “Psychiatry Collective” is now open to all verified mental health clinicians and practice owners. "We're about halfway up the mountain," explains Osmind Cofounder & CEO, Lucia Huang. "Like oncology decades ago, psychiatry is evolving from subjective assessments toward more precise, objective measurements of mental health." Every day brings new research, treatments, and care approaches. The problem? It's impossible to keep up with it all alone. The Osmind Psychiatry Collective is a community to learn, connect, and grow: -Verified treatment-specific spaces for Spravato?, TMS, and ketamine -modalities -20+ expert-designed clinical templates and protocols -10-minute research digests that turn complex studies into actionable insights -Private Practice Vault with resources medical school never gave you -Direct access to experts in the field via live and recorded events Don't miss this opportunity to join thousands of verified clinicians within the Psychiatry Collective—free for a limited time ($120 annual value): https://lnkd.in/d54vDa3Q

This is really something. I've noticed (I'm sure you have too) that AI "helpers" have this terrible habit of inserting "thrilled!" and "groundbreaking!!" and similar words into everybody's writing, it's unfortunate, nobody is THAT excited about EVERYTHING ... but this is inspiring me to use a word I strive to use very sparingly: Gamechanger. Only thing I might love more than TMS would be Backpack TMS. Why? Well because I was born in 1974, and that means I always wanted to be a Ghostbuster. Isn't that reason enough? But another reason? TMS is amazing, it really is. I still remember where I was sitting the first time somebody told me you could use electromagnetic induction to electrically stimulate brain, and then the Admiral bought me one, and it is just my favorite thing to do for fifteen years BUT - you still have to sit still in a chair in an office for at least 20min to receive the treatment. That's pretty much OK for treating depression ... the Tourette's case I did years ago was a bit of a challenge but a great staff and some Spiderman videos and we got through it ... but what if you want to use it to treat migraine headaches before they start? (Somebody DID do that - if you're only doing a couple pulses, that's not that hard, but still.) OR what if you're trying to treat an injured brain and you'd really like to induce some neuroplasticity while your patient is practicing their exercises ...? Walking on a treadmill? There just isn't a way to strap a full dentist chair along with a coil that's about as heavy as Thor's Hammer across the shoulders! But this thing? The coil itself is about 1.7Kg (about 3.74lbs) and the stimulator unit isn't that much heavier. They've already demonstrated using it while walking (seems slightly easier than chewing gum and walking at the same time ...) This opens up an entire arena for TMS that just wasn't feasible previously because of the size and weight of a TMS device. So to quote my oft used AI helper companions: I am THRILLED to be reading about this GROUNDBREAKING new research into the design of TMS devices for the future!! Because if this kind of thing really works? It really is a game changer. https://lnkd.in/esm-TXZu

?? “If you want to move quickly, you're going to need outside capital." But at what cost? Two psychiatrists who've built, scaled, and sold practices reveal what they wish they'd known sooner: -Why rushing to investors can be your biggest mistake -The stark differences between private equity (seeking quick flips) and venture capital (betting on tech) -How to maintain control when scaling -Why being an excellent clinican is your greatest business advantage Dr. William Sauvé, MD went from a $9,000 startup to a multi-state, publicly-traded network. Dr. Carlene MacMillan, MD, FCTMSS,DFAACAP built, sold, and rebuilt practices through multiple investment models. Their candid advice? "Never, ever be afraid to walk away." And "pick your business partners with the same care as a romantic partner." Whether you're starting out or considering growth options, shortcut their hard-earned lessons. Learn the business side they don't teach in medical school. ?? https://lnkd.in/d9sg8RxS

Join Foundation for the Advancement of Clinical TMS (FACTMS) for a virtual event led by an all-female panel, including Osmind's VP of Clinical Innovation, Carlene MacMillan, MD, FCTMSS,DFAACAP! When: March 25 at 8 pm ET/5 pm PT

Exciting news: Our co-founder and CEO, Lucia Huang, has been named to Inc.'s 2025 Female Founders 500! ?? Inc. Magazine's eighth annual list highlights female founders who are challenging the status quo and tackling some of the world's biggest problems. This year's honorees collectively generated $9B in revenue and secured $10.6B in funding, demonstrating exceptional leadership amid challenging market conditions. Under Lucia's leadership, Osmind empowers clinicians with tools that help patients access life-changing mental healthcare. Join us in congratulating Lucia alongside this remarkable group of business leaders!

"I dream of a future where my psychiatry services are barely needed—because we've successfully treated, prevented, or even eradicated mental illness." Dr. Brittany Albright MD, MPH joins Osmind as Medical Advisor, bringing expertise from founding South Carolina's largest physician-owned psychiatry practice. Her three-part vision for transforming mental healthcare: 1. Universal access without barriers: "Mental healthcare shouldn't be a luxury—it should be something everyone can access without jumping through hoops." 2. Rapid adoption of breakthrough treatments: "From neuromodulation to psychedelics, we're on the cusp of transforming how we treat mental illness—but we need to push for affordability, safe use, best practices, and better access." 3. Let's use technology to bring humanity back into medicine: "Let's shift the focus back where it belongs—on the patient sitting in front of us, not the computer screen." Read Dr. Albright's full perspective: https://lnkd.in/dD8rZzwh

Important Update for Psychiatrists: FDA Ends Clozapine REMS Program The FDA removed the REMS requirements for clozapine, eliminating a significant barrier that has limited access to this highly effective treatment for schizophrenia. In our latest blog, Osmind CMO Dr. William Sauvé, MD, and Brittany Albright MD, MPH share insights from our recent fireside chat: -The fascinating history of clozapine's development and challenges -Real-world case examples showing how REMS complicated patient care -Expert perspectives on whether prescribing patterns will change -Best practices for clozapine management in this new regulatory environment -The evidence is compelling: clozapine substantially outperforms other options for treatment-resistant cases, with 30% of patients improving vs. just 4% on alternatives. Yet administrative hurdles have kept this medication out of reach for many who could benefit. How will this regulatory shift affect your practice? Read the full analysis here: https://lnkd.in/dpGWAWuc